2024-03-28T10:30:46Z
https://soar-ir.repo.nii.ac.jp/oai
oai:soar-ir.repo.nii.ac.jp:00020848
2022-12-14T04:20:20Z
461:462
Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study
Fujimoto, Keisaku
Yamazaki, Haruna
Ura, Midori
Kitaguchi, Yoshiaki
bronchodilator agents
clinical respiratory medicine
COPD
respiratory function tests
quality of life
Background and objective: The difference in efficacy of long-acting muscarinic antagonists (LAMAs) and long-acting beta(2)-agonists (LABAs) for dynamic lung hyperinflation (DLH) in COPD is unclear. The purpose of this study was to elucidate the difference in efficacy of LAMA and LABA alone and the combination thereof for DLH. Subjects and methods: Thirty stable patients were enrolled and randomly divided into two groups following baseline measurements. One group was treated with 5 mu g tiotropium (Respimat inhaler) for 4 weeks following a 4-week treatment with 150 mu g indacaterol, while the other group was treated with indacaterol for 4 weeks following a 4-week treatment with tiotropium. For both groups, these treatments were followed by a combination of the two drugs for 4 weeks. Pulmonary function tests, including DLH evaluated by metronome-paced incremental hyperventilation and exercise tolerance evaluated by the shuttle-walk test, were performed at the end of each treatment period. Results: In total, 23 patients completed this study. Both tiotropium and indacaterol alone significantly increased forced expiratory volume in 1 second, exercise tolerance, and improved health status. Tiotropium significantly improved DLH, but indacaterol did not. The combination therapy resulted in further improvements in lung function and exercise tolerance, but not in DLH. Conclusion: The efficacy of tiotropium in inhibiting DLH following metronome-paced incremental hyperventilation may be superior to that of 150 mu g indacaterol, although the effects on airflow obstruction were the same, and the combination therapy showed further improvement in airflow obstruction, but not in DLH.
Article
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.12:3195-3201(2017)
journal article
DOVE MEDICAL PRESS LTD
2017-11-01
application/pdf
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
12
3195
3201
1178-2005
https://soar-ir.repo.nii.ac.jp/record/20848/files/15K01281_03.pdf
eng
29138547
https://www.ncbi.nlm.nih.gov/pubmed/29138547
10.2147/COPD.S149054
https://doi.org/10.2147/COPD.S149054
© 2017 Fujimoto et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution © Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).